Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.

Current evidence is not sufficient to support levosimendan as superior to dobutamine or as an optimal adjunct in severe sepsis and septic shock. More large-scale randomised trials are necessary to validate levosimendan use in sepsis.